Alyteserin-2a [G3K]

General Information


DRACP ID  DRACP02088

Peptide Name   Alyteserin-2a [G3K]

Sequence  ILKKLLSTAAGLLSNL

Sequence Length  16

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic (Derived from Alyteserin-2a)

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
A549 Lung adenocarcinoma Carcinoma LC50=100 μM CellTiter-Glo Luminescent Cell Viability assay 24 h 1

Hemolytic Activity  Human erythrocytes: 50% Hemolysis=105 µM

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antimicrobial; Antifungal



Structure Information


PDB ID  Not available

Predicted Structure  DRACP02088

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C76H139N19O21

Absent amino acids  CDEFHMPQRVWY

Common amino acids  L

Mass  192281

Pl  10.81

Basic residues  2

Acidic residues  0

Hydrophobic residues  9

Net charge  2

Boman Index  1189

Hydrophobicity  105.63

Aliphatic Index  183.13

Half Life 
  Mammalian: 20 hour
  Yeast: 30 min
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  5

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 22965637

Title  Transformation of the naturally occurring frog skin peptide, alyteserin-2a into a potent, non-toxic anti-cancer agent

Doi 10.1007/s00726-012-1395-7

Year  2013

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_4360

DRACP is developed by Dr.Zheng's team.